A Novel Approach against Vascular Intimal Hyperplasia Through the Suppression of Girdin

Hiroki Miyachi, MD, PhD, Masahide Takahashi, MD, PhD, and Kimihiro Komori, MD, PhD

Department of Vascular Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

Received: December 2, 2014; Accepted: April 10, 2015

Corresponding author: Kimihiro Komori, MD, PhD. Department of Vascular Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
Tel: +81 52 744 2224, Fax: +81 52 744 2226
E-mail: komori@med.nagoya-u.ac.jp

Intimal hyperplasia is an impediment to patency in both arteries after percutaneous angioplasty (PTA) and vein graft. It is well known that migration and proliferation of vascular smooth muscle cells (SMCs) influence the vascular remodeling process, there are no therapies to prevent intimal hyperplasia of post-PTA arteries and vein grafts. Girdin (girders of actin filaments), also known as Ga-interacting vesicle associated protein (GIV) is a novel actin-binding Akt substrate. Girdin is highly expressed in limited types of cells such as smooth muscle cells, neuroblasts, and cancer cells. Girdin is involved in the cell migration, proliferation and remodeling of actin filaments. This study revealed that Girdin is involved with intimal hyperplasia in carotid arteries after balloon injury and vein grafts and vascular SMCs migration and proliferation. There are suggestions that Girdin has pivotal roles in migration and proliferation of vascular SMCs and that gene therapy targeting Girdin could be a novel therapeutic strategy for restenosis after PTA and vein graft failure.

Keywords: intimal hyperplasia, Girdin, gene therapy

Introduction

Vascular injury caused by angioplasty induces deendothelialization, which promotes the deposition of platelets at the injured site and subsequent recruitment of leukocytes. Growth factors and cytokines released from platelets, leukocytes and vascular smooth muscle cells (SMCs) stimulate the migration and proliferation of VSMCs, which results in neointima formation and restenosis.1–3

Moreover, late graft failure of autologous vein grafts is also associated with intimal hyperplasia resulting from the migration and proliferation of vascular smooth muscle cells.

The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is a key regulator of several processes such as cell survival, proliferation and growth downstream of these humoral factors.4–6 Accumulating evidence suggests that the PI3K-Akt pathway and its downstream components also play essential roles in vascular remodeling.7–11 However, the underlying molecular mechanisms are not completely understood.

A search for Akt-binding proteins led to the identification of Girdin (girders of actin filament), also known as Akt phosphorylation enhancer (APE) and G-interacting vesicle associated protein (GIV).12–14 Girdin is a large 220-kDa protein with unique amino- and carboxyl-terminal domains flanking a long coiled-coil region. Girdin forms oligomers through its amino-terminal domain and coiled-coil region. The carboxyl-terminal domain contains the actin-binding site and the phosphatidylinositol phosphate-binding motif located near the Akt phosphorylation site (serine 1416). Therefore, Girdin is postulated to crosslink actin filaments and to anchor them to the plasma membrane in quiescent cells. In response to growth factors, Akt phosphorylates Girdin at serine 1416, and the phosphorylated Girdin accumulates in the lamellipodia of migrating cells, leading to the rearrangement of the actin cytoskeleton.12 To our knowledge, Girdin is the only actin-binding protein that is directly phosphorylated by Akt.

This paper reviews whether Girdin modulates the vascular remodeling process in vitro and in vivo, and the ability of Girdin to induce cell migration, proliferation and survival in VSMCs. In this paper we introduce the vector for gene delivery to the vasculature, and a novel therapeutic strategy for restenosis after percutaneous angioplasty (PTA) and vein graft failure.
Intimal Hyperplasia

The process of intimal hyperplasia is common to various forms of vascular diseases, such as atherosclerosis, restenosis, and transplant vasculopathy. In response to vascular injury, the medial smooth muscle cells proliferate and migrate into the intima, where they proliferate and secrete abundant extracellular matrix to form the neointima. In another way, various biological changes that lead to intimal hyperplasia occur when a vein graft is implanted in the arterial circulation. Those changes include the migration and invasion of inflammatory cells, a loss of endothelial cells, an increased shear stress, and migration and proliferation of VSMCs of vein grafts.

Girdin and Intimal Hyperplasia

Girdin is expressed in VSMCs but not endothelial cells in large vessels with a thick smooth muscle layer, such as carotid and femoral arteries. Girdin is also localized in media of vein.

It is reported that Girdin is upregulated in developing neointima. Miyake et al. reported that as the neointima grew thicker, enhanced expression and phosphorylation of Girdin were observed in the neointima of rat balloon injury (BI) model with immunohistochemical assessment. Both the expression and the phosphorylation of Girdin in the neointima peaked at 14 days after BI, and persisted for at least 28 days. Then, the level dropped to the baseline by 42 days after BI. We previously reported Girdin expression in rabbit vein graft. Girdin was located in the neointima rather than in the media as the neointima thickened. By immunohistochemical analysis, Girdin was detected especially in neointima of vein grafts. The expression of Girdin was increased over time and peaked at 14 days after bypass grafting. Moreover, we compared expression of Girdin in vein grafts with poor and normal runoff in which the neointima was clearly thickened to determine whether Girdin affects intimal hyperplasia in vein grafts. Girdin expression significantly increased during neointima formation at 7 and 14 days after bypass grafting in poor conditions.

Fig. 1 Vein grafts at 14 days post-operation were subjected to immunofluorescence staining using sheep IgG as a negative control or anti-Girdin antibody (red), and anti-α-SMA antibody (green). Cell nuclei were labeled with DAPI. Representative photos at low magnifications (upper and middle panel) are presented. The boxed area is magnified (lower panel). Bars: 200 µm (upper and middle); 50 µm (lower). α-SMA: α-smooth muscle actin

Fig. 2 Venous SMCs were stained using anti-Girdin antibody and anti-β-actin antibody. Girdin localizes to actin stress fibers. Bar: 20 µm. SMCs: smooth muscle cells

Fig. 3 Venous SMCs were stimulated with PDGF-BB (20 ng/ml) for 10 minutes and stained with anti-β-actin antibody. Red dotted lines denote lamellipodia at the leading edge. Arrowheads denote less polarized and less extended membrane protrusions compared with the control cells. Bar: 20 µm. SMCs: smooth muscle cells
markedly reduced intimal thickening after the grafting operation. So, Girdin is essential for intimal hyperplasia in vivo.

**Girdin Localization**

Miyake et al. reported that most of the cells constituting the neointima revealed positive staining for Girdin and α-smooth muscle actin (α-SMA) in rat BI model. In addition, Girdin localization was confirmed in 14-day-old vein grafts by immunofluorescence staining using anti-Girdin antibody and anti-α-SMA antibody (Fig. 1). Girdin localizes to α-SMA+ cells in the media and neointima. Cells that were both Girdin+ and α-SMA+ existed mainly in the vein graft neointima at 14 days after bypass grafting. This finding suggests that Girdin is upregulated in the developing neointima.

**Gene Transfer and Inhibition of Intimal Hyperplasia**

To further analyze the involvement of Girdin in vascular remodeling, an adenoviral vector encoding shRNA directed against Girdin was transferred into balloon-injured arteries to selectively inhibit the expression of endogenous Girdin. The introduction of shRNA against Girdin attenuated the neointima formation without affecting reendothelialization. On the other hand, siRNA that targets Girdin was mixed with atelocollagen, which stabilizes and releases nucleic acid reagents slowly, and the mixture was applied perivascularily to the vein grafts during surgery. Girdin knockdown via perivascular application of siRNA using atelocollagen markedly reduced intimal thickening after the grafting operation. So, Girdin is essential for intimal hyperplasia in vivo.

**Girdin Affects Cell Proliferation But Not Cell Survival During Intimal Hyperplasia**

Cell migration, cell proliferation, and apoptosis of vascular SMCs are major steps in intimal hyperplasia. Miyake et al. examined the cell proliferation and apoptosis in balloon injured arteries using immunostaining for proliferating-cell nuclear antigen (PCNA) and TUNEL staining, respectively. The knockdown of Girdin significantly reduced the PCNA labeling indices in the neointima, but had no apparent effect on TUNEL labeling indices. We also examined cell proliferation and apoptosis in vein grafts using immunostaining, and the results suggest that Girdin affects cell proliferation but not cell survival.

**Girdin Involves in Rearrangement of Actin Cytoskeleton of VSMCs**

Immunocytochemical analysis revealed Girdin localized on actin stress fibers in primary SMCs. When Girdin-depleted SMCs are stimulated with serum, the formation of thick stress fibers significantly decreased compared with control SMCs. The stimulation with PDGF-BB in the Girdin-depleted cells results in attenuation of the wide extension of lamellipodia at the leading-edge making membrane protrusions smaller.

These results show that actin remodeling of lamellipodia in migrating SMCs require Girdin.
Girdin Depletion Inhibits VSMCs Migration and Proliferation In Vitro

The function of Girdin on the migration and proliferation of human arterial VSMC was examined by Miyake et al. The involvement of Girdin in cell migration was examined using wound-healing assays. The number of cells that migrated into the wounded area and the migration velocity were significantly reduced in the Girdin-depleted cells as compared to the control cells. Moreover, to assess the effect of Girdin on hVSMC proliferation, MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] colorimetric assays were performed. On day 5 after the transfection of siRNAs, the proliferation of the Girdin-depleted cells was markedly suppressed.

We also inquired whether Girdin depletion suppressed primary venous SMCs migration by wound healing assays. Girdin depletion showed markedly reduced migration distance. We observed fewer cells migrating into the wounded area as seen in arterial SMCs. Furthermore, water-soluble tetrazolium salt (WST)-1 assays showed that proliferation was significantly suppressed using Girdin-depleted SMCs. These findings show that Girdin depletion inhibits migration and proliferation of SMCs in vitro.

Conclusion

These studies demonstrated that Girdin regulates the remodeling of the actin cytoskeleton, as well as the migration and proliferation of both arterial and venous SMCs. Transduction of shRNA directed against Girdin into the rat artery suppressed intimal hyperplasia after balloon injury. In addition, atelocollagen-delivered siRNA targeting Girdin reduced intimal thickening after the grafting operation. This was accompanied by decreased cell migration and proliferation of VSMCs (Fig. 4).

In conclusion, Girdin is essential for the rearrangement of the actin cytoskeleton, as well as for the migration and proliferation of both arterial and venous SMCs, which is vital for intimal hyperplasia. The Akt/Girdin signaling pathway might have functions as a crucial regulator of vascular remodeling. Therefore, Girdin may be an important therapeutic target for vascular proliferative diseases such as restenosis and atherosclerosis and late graft failure of autologous vein grafts.

Disclosure Statement

The authors declare no conflict of interest.

References

New Gene Therapy for Girdin in Intimal Hyperplasia


